Devax CE marks Axxess stent
This article was originally published in Clinica
Executive Summary
Devax's Axxess bifurcated drug-eluting stent is now available for sale in Europe, after the firm CE marked it. The self-expanding Nitinol stent, which elutes biolimus A9, is intended for bifurcated lesions. These occur in around 20% of patients treated with coronary angioplasty and stenting, the Lake Forest, California company estimates. Bifurcations are associated with an increased frequency of major adverse cardiac events compared with lesions in straight vessel segments, according to large trials such as SYNTAX and LEADERS. The 302-patient DIVERGE study, published in the Journal of the American College of Cardiology in March 2009, showed higher rates of clinical success and lower rates of restenosis with Axxess compared with other studies of bifurcated lesions.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.